Algernon Submits for Ethics Approval for Phase 2 IPF and Chronic Cough Study

UF startup Algernon Pharmaceuticals Inc., a clinical-stage pharmaceutical development company, is pleased to announce that it has submitted for ethics approval in Australia for its planned Phase 2 study of its re-purposed drug NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough.

Ethics submission is the next step in the company’s clinical development program of its re-purposed drug Ifenprodil for IPFand chronic cough. The company has also recently started to expand its investigation of Ifenprodil for acute lung injury (ALI) and COVID-19.

Learn more about Algernon Submits for Ethics Approval for Phase 2 IPF and Chronic Cough Study.